In clinical practice, we often deal with patients who suffer from non-alcoholic fatty liver
disease (NAFLD) concurrent with type 2 diabetes mellitus (T2DM). The etiopathogenesis of …

Global estimates of prevalence, deaths, and disability-adjusted life years (DALYs) from the
Global Burden of Diseases, Injuries, and Risk Factors Study 2019 were examined for …

Objectives This network meta-analysis aims to compare the efficacy and safety of new anti-
diabetic medications for the treatment of non-alcoholic fatty liver disease (NAFLD). Materials …

Background Nonalcoholic fatty liver disease is associated with an increased cardiovascular
disease (CVD) risk, although the exact mechanism (s) are less clear. Moreover, the …

ABSTRACT Introduction and Objectives Type 2 Diabetes Mellitus (T2DM) is comorbidity
commonly presenting with fatty liver. A recently proposed definition of" metabolic associated …

Background & Aims: Hypertension (HTN) is a common comorbidity in non-alcoholic fatty
liver disease (NAFLD) affecting up to 40% of individuals. Yet, the impact of HTN and its …

Abstract Background and Aim Metabolic dysfunction‐associated steatotic liver disease
(MASLD) has been proposed as an alternative for the validated definition of metabolic …

Aim To examine the prevalence and prognosis of hepatic steatosis and fibrosis in post‐
acute myocardial infarction (AMI) patients. Methods Patients presenting with AMI to a tertiary …

Lean patients with MAFLD have an initial adaptive metabolic response characterised by
increased serum bile acids and Farnesoid X Receptor (FXR) activity. How this adaptive …

Background Metabolic associated fatty liver disease (MAFLD) was recently proposed as an
alternative name change for better encapsulation of disease. However, there exists a …